Since the first biosimilar drug was approved in 2006, the EU has led the way in biosimilar regulation. Over the last decade, the EU has authorized the most biosimilars globally, gathering significa...
Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on ha...
Find More
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative potential as a new type of cancer treatment that utilizes the immune system to fight the disease. It involves the process where genetically engineered T cells (patient/donor) express a chimeric antigen receptor to target a specific ...
Find More
Blood cancers have seen tremendous advancements in the past few years due to the dedication of researchers pulling out all the stops to churn out therapeutic innovations intended to be of service to suffering patients. These experimentations and their upshots are always brought to us through various platforms, the ...
Find More
Boston Scientific initiates trial to evaluate industry's first Modular CRM System On December 02, 2021, Boston Scientific Corporation started the MODULAR ATP clinical trial to examine the safety, performance, and effectiveness of the mCRM™ Modular Therapy System. The system comprises of two cardiac ...
Find More
Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organisation for log...
Find More
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a relatively new immunological checkpoint that has been studied as a potential immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor containing an Ig-like V-type domain in its cytoplasmic domain and an ITIM in its extracellular domain. It'...
Find More
The expiration of many biologic drugs patents has sparked biosimilar development and boosted the biosimilar market growth. Biosimilars are alternative versions of innovator biologic drugs. These are biological products that are similar replicas of the biopharmaceuticals that inspired them. Biosimilars are sometimes...
Find More
GE Healthcare, Optellum collaborate for AI-based lung cancer diagnosis GE Healthcare has collaborated with Optellum to progress precision diagnosis and lung cancer treatment with artificial intelligence. The partnership is zeroed in on helping healthcare providers to evaluate the malignancy of a lung nodule a...
Find More
Follicular Lymphoma is the second most widespread non-Hodgkin lymphoma subtype, accounting for roughly 20% of all NHL cases. It is a slow-growing (low-grade) NHL that develops from B cells. It is called follicular lymphoma because the abnormal B cells usually develop in clumps called ‘follicles’ inside lymph nodes....
Find More
The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....
Find More
A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 mi.....
Find More
Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from .....
Find More
Digital therapies are evidence-based clinical approaches powered by software applications designed t.....
Find More
Schizophrenia is a severe mental illness that interferes with a person's ability to think clearly, m.....
Find More
Lupus Nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE),.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
